RecruitingNCT06178822

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

Sponsor

Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)

Enrollment

3,300 participants

Start Date

Oct 25, 2022

Study Type

OBSERVATIONAL

Conditions

Sepsis Infections Septic Shock Infection, Bacterial Sepsis, Severe Infection Viral Infections, Respiratory

Summary

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying No intervention for people with infection viral, infection, bacterial, and other related conditions. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

There is no intervention

Locations(3)

Flevoziekenhuis

Almere Stad, Flevoland, Netherlands

Amsterdam UMC, location VUMC

Amsterdam, North Holland, Netherlands

Amsterdam UMC, location AMC

Amsterdam, North Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06178822

Related Trials

Long-term Assessment of Patients Treated in the ICU for Sepsis

NCT075027941 location

Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation

NCT075301461 location